OSE Immunotherapeutics Receives a Milestone Payment of €5.4 Million From Bpifrance for SIRPα-Antagonist Monoclonal Antibody BI 765063

    NEXT STORY
    Oasmia presents Q1 report through audiocast on September 26
    PREV STORY
    Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Argos Therapeutics Added to the Russell 2000® Index

    DURHAM, N.C., June 27, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology ...

    author_avatar
    NASDAQ Market News

    Celsion Corporation to Hold First Quarter 2018 Financial Results Conference Call on Friday, May 11, 2018

    LAWRENCEVILLE, N.J., May 04, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today ...

    author_avatar
    NASDAQ Market News

    Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections by FDA

    -PDUFA action date set for June 30, 2019-DUBLIN, Ireland, Jan. 04, 2019 (GLOBE NEWSWIRE) ...

    author_avatar
    NASDAQ Market News